| Active Ingredient (Brand Name) | Disease Area | Marketing Authorisation |
| Chenodeoxycholic acid (Chenodeoxycholic acid Leadiant) | Cerebrotendinous Xanthomatosis | UK, EU, Israel, Switzerland*, Chile*, Colombia* |
| Procarbazine (Natulan) | Hodgkin Disease, Non-Hodgkin Lymphomas, Brain Tumours, Chronic Lymphocytic Leukaemia, Small Cell Lung Cancer** | France, Spain, Germany, Italy, Russia, Netherlands, Switzerland*, Hong Kong*, China, Australia |
Brand names may differ in different countries
*Marketing Authorisations held by partner organisations
**Indications may differ between countries and each indication may not be authorised in every country
Last update: July 2022
Important Note
For patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition, you can contact us on safety@leadiantbiosciences.com.
For healthcare professionals: if you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your country or contact us at safety@leadiantbiosciences.com.
If your residence is in the U.S. or Canada, please consult the North American website for details on safety reporting.
